Bedtime Aspirin and Blood Pressure: A Plausible Signal, Not Proof

For people already prescribed low-dose aspirin after a heart attack or stroke, taking it at bedtime may modestly improve 24-hour blood pressure compared with taking it in the morning. The best direct summary of the evidence estimates a 3.6 mmHg lower systolic pressure and a 1.9 mmHg lower diastolic pressure with bedtime dosing. Those numbers deserve attention. So do the reasons not to overread them.

The evidence comes from short trials, measures a surrogate rather than heart attacks or strokes, and includes research connected to the HYGIA chronotherapy group, whose larger blood-pressure timing studies have drawn serious scientific scrutiny. Bedtime aspirin is a reasonable question for a prescriber if you already need aspirin for secondary prevention. It is not a reason to start aspirin on your own.

The direct evidence: a small blood-pressure advantage

A 2024 systematic review and meta-analysis by Nadeem et al. pooled six randomized controlled trials comparing bedtime with morning aspirin. Of 1,470 enrolled participants, 1,086 completed the trials: 545 took aspirin at bedtime and 541 took it in the morning. Five trials used 100 mg daily; one used 75 mg. Follow-up lasted 12 weeks to three months.

On 24-hour ambulatory blood-pressure monitoring, bedtime dosing favored lower pressure by about 3.6 mmHg systolic and 1.9 mmHg diastolic. Ambulatory monitoring matters more than a single clinic reading because it captures daytime pressure, nighttime pressure, and the normal overnight dip. A sustained systolic difference of 3 to 4 mmHg could matter over years. These trials, however, lasted weeks, not years, and did not test whether the timing change prevented myocardial infarction, stroke, or cardiovascular death.

That distinction is the whole case in miniature: the trials found a difference in a validated cardiovascular-risk marker, not proof of better clinical outcomes. The pooled result also cannot tell us whether the effect persists after the first few months or whether it changes with aspirin dose.

Why the hypothesis makes biological sense

Blood pressure does not hold still for 24 hours. It usually rises before waking, levels off during the day, and falls during sleep. The renin-angiotensin-aldosterone system, autonomic nervous system, vascular tone, endothelial function, and platelet activity all follow daily rhythms. People whose blood pressure does not fall by at least 10% overnight, often called non-dippers, tend to have greater cardiovascular risk.

A 2021 review by Smolensky and colleagues describes how these rhythms can alter the pharmacokinetics and pharmacodynamics of cardiovascular medicines. In other words, the body can process and respond to the same dose differently at different hours. That makes an aspirin timing effect plausible; it does not establish that one exists in every person.

Nadeem et al. discuss three proposed routes for a bedtime effect. Overnight activation of the renin-angiotensin-aldosterone system may make the nocturnal period more responsive to an intervention that influences vascular regulation. Aspirin may also promote nitric-oxide-related vasodilation when sympathetic activity is lower during sleep. The wider role of nitric oxide in endothelial function is well established: a 2025 meta-analysis of randomized trials of inorganic nitrate found improved endothelial function versus control, consistent with the nitrate-nitrite-nitric oxide pathway affecting vascular biology.

The third route involves platelets. Platelet turnover peaks overnight, and one randomized trial cited in the aspirin meta-analysis found greater reduction in platelet aggregation with bedtime administration. That finding fits aspirin's main antiplatelet action. It still does not show that changing the clock time prevents another cardiovascular event.

The problem inside the pooled estimate

The 2024 meta-analysis contains a major credibility problem: one of its six randomized trials had authors affiliated with the HYGIA chronotherapy research program. HYGIA produced some of the most influential claims that bedtime medication timing greatly improves cardiovascular outcomes. Those claims have faced scrutiny because their effect sizes appeared unusually large and independent work has not reproduced them.

The aspirin meta-analysis did not report a sensitivity analysis excluding HYGIA-affiliated data. That omission matters because the available information does not show how much of the 3.6/1.9 mmHg estimate depends on that research group. The remaining trials may still support a bedtime advantage, but the pooled analysis does not resolve the question.

Other limits point in the same direction. The total number of completers was 1,086, modest for a cardiovascular endpoint. All studies were short. The trials mixed 75 mg and 100 mg doses without a dose-specific analysis. Generalizability remains unsettled, particularly because earlier literature in this area drew heavily from Chinese-origin populations. The meta-analysis search ended in August 2020, before several developments that now shape the field.

What the TIME trial does—and does not—settle

The later UK TIME trial tested evening versus morning dosing of participants' usual antihypertensive medicines, including ACE inhibitors, angiotensin-receptor blockers, calcium-channel blockers, and diuretics. It was a large pragmatic randomized trial with major cardiovascular events as its endpoint. It found no advantage for evening dosing.

TIME did not test aspirin, and it did not refute an aspirin-specific effect on ambulatory blood pressure. Its relevance is narrower and more useful: a timing-related change in blood pressure or physiology does not automatically become fewer heart attacks and strokes. The comparison differs in drugs, population, and endpoints, but it weakens any broad claim that bedtime dosing is inherently superior for cardiovascular treatment.

Chronobiology remains real medicine, not horoscope medicine. The clinical payoff from manipulating the clock, though, has to survive independent outcome trials.

Aspirin timing matters only after aspirin itself makes sense

For primary prevention—taking aspirin to prevent a first cardiovascular event—the timing question usually comes second to the prescription question. In the prevention data summarized by Nadeem et al., cardiovascular event rates were 0.51% with aspirin and 0.57% with control, while major gastrointestinal and extracranial bleeding occurred at annual rates of 0.10% and 0.07%, respectively. Small absolute benefits can disappear quickly when bleeding enters the calculation.

The USPSTF's 2022 recommendation advises individualized decisions for adults ages 40 to 59 with at least a 10% 10-year cardiovascular risk and no increased bleeding risk; it recommends against initiating aspirin for primary prevention in adults 60 or older. These recommendations address starting aspirin, not the timing of aspirin already prescribed for another indication.

Secondary prevention is different. Among people with established cardiovascular disease, the meta-analysis reports cardiovascular event rates of 6.7% with aspirin and 8.2% with control. That larger absolute risk leaves more room for aspirin's established benefits. If you take aspirin after a prior myocardial infarction, stroke, or other established vascular disease, asking your clinician whether bedtime dosing fits your regimen is reasonable. Do not switch timing without considering other medications, reflux or stomach symptoms, adherence, and the reason aspirin was prescribed.

Where lifestyle work fits

No clock-based aspirin adjustment substitutes for blood-pressure treatment with outcome evidence. In hypertensive patients, a systematic review and meta-analysis of nine HIIT trials involving 569 patients found improvements in blood pressure and cardiac autonomic responses. A 2025 systematic review of relaxation techniques also found that approaches such as diaphragmatic breathing and progressive muscle relaxation can reduce stress and improve quality of life in people with hypertension or cardiovascular disease. These studies do not validate bedtime aspirin; they show that autonomic state and blood pressure remain modifiable through more than a pill schedule.

The practical verdict

Bedtime aspirin has a plausible circadian rationale and a modest ambulatory blood-pressure signal in six short randomized trials. It lacks independent, long-term evidence that it reduces cardiovascular events, and the pooled estimate has an unresolved HYGIA-related integrity concern.

If aspirin is already part of your secondary-prevention treatment, bedtime dosing is a low-burden topic for a clinician conversation—not a proven upgrade. If you are healthy and considering aspirin for primary prevention, focus first on whether aspirin's expected benefit exceeds its bleeding risk. Timing cannot rescue a medication that is a poor fit.

The broader lesson is worth keeping: medication timing can affect biology, but a mechanistic story and a shifted biomarker do not equal better outcomes. Ask what was tested, for how long, against what comparator, and whether anyone measured the events people actually fear.